menu
    • menu
    [{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Tucidinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HUYA Bioscience International \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tucidinostat","moa":"HDAC","graph1":"Oncology","graph2":"Approved","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HUYA Bioscience International \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tucidinostat

    Menu

    Tucidinostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HUYA Bioscience International

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            HUYA Bioscience International

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tucidinostat

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan

                            Details : Hiyasta (HBI-8000) is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer. it targets class I histone deacetylases and suppresses expression of viral oncogene HTLV-I bZIP factor, NF-kB and the inflammasome in...

                            Brand Name : Hiyasta

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2021

                            Lead Product(s) : Tucidinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HUYA Bioscience International

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            HUYA Bioscience International

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tucidinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Meiji Seika Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and O...

                            Details : HUYABIO will complete the development of HBI-8000 for PTCL and ATL in Japan for commercialization by Meiji who will hold exclusive sales and marketing rights.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 08, 2020

                            Lead Product(s) : Tucidinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Meiji Seika Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth